Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

10.47
+1.4315.82%
Volume:7.86M
Turnover:80.18M
Market Cap:652.19M
PE:-3.03
High:11.20
Open:9.04
Low:8.97
Close:9.04
52wk High:71.50
52wk Low:7.76
Shares:62.29M
Float Shares:40.64M
Volume Ratio:0.86
T/O Rate:19.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4602
EPS(LYR):-3.4602
ROE:-207.10%
ROA:-16.77%
PB:3.28
PE(LYR):-3.03

Loading ...

Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official

MT Newswires Live
·
19 mins ago

uniQure therapy called failed product by FDA official, Bloomberg says

TIPRANKS
·
1 hour ago

US-Listed Shares of Uniqure Nv Rise Nearly 20%

THOMSON REUTERS
·
2 hours ago

FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial

Benzinga_recent_news
·
2 hours ago

uniQure call volume above normal and directionally bullish

TIPRANKS
·
3 hours ago

Concerns spurred by FDA push for ‘sham’ brain surgery trial, Bloomberg says

TIPRANKS
·
Yesterday

What's Going On With uniQure Stock Wednesday?

Benzinga_recent_news
·
Mar 04

Berger Montague alerts uniQure investors to class action lead plaintiff deadline

Reuters
·
Mar 04

Rosen Law Firm Urges uniQure Investors to Meet April 13 Lead Plaintiff Deadline

Reuters
·
Mar 04

These Analysts Cut Their Forecasts On uniQure Following Q4 Results

Benzinga
·
Mar 03

Chardan Cuts Price Target on uniQure to $16 From $53, Keeps Buy Rating

MT Newswires Live
·
Mar 03

uniQure Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 03

uniQure price target lowered to $16 from $53 at Chardan

TIPRANKS
·
Mar 03

Uniqure Nv : Mizuho Cuts to Neutral From Outperform; Cuts Target Price to $12 From $33

THOMSON REUTERS
·
Mar 03

Uniqure Nv : Wells Fargo Cuts to Equal Weight From Overweight; Cuts Target Price to $15 From $60

THOMSON REUTERS
·
Mar 03

Barclays Reaffirms Their Hold Rating on uniQure (QURE)

TIPRANKS
·
Mar 03

uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments

TIPRANKS
·
Mar 03

uniQure (QURE) was downgraded to a Hold Rating at Mizuho Securities

TIPRANKS
·
Mar 03

UniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns

Simply Wall St.
·
Mar 03

FDA Mandates Phase III Trial for uniQure's Huntington's Disease Gene Therapy, Blocking Market Approval and Sending Shares Down 33%

Stock News
·
Mar 03